Report Overview

The EU Diabetes Mellitus Type-II Drugs market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of 5.6% during the forecast period

Diabetes Mellitus Type-II is becoming an increasingly common health condition, which can disable patients and potentially lead to fatal health complications. EU spending is approximately. 9% of the total healthcare expenditure. Diabetes Mellitus Type-II is one of the leading causes of cardiovascular diseases, blindness, kidney failure, and lower limb amputation. There are about 60 million people with diabetes in the EU, or about 10.3% of men and 9.6% of women aged 25 years and over. Eating high levels of refined carbohydrates and saturated fat and not enough fruits and vegetables contributes to weight gain, thereby increasing the risk of diabetes mellitus type-II. Studies have shown that just 30 minutes of moderate exercise a day, five days a week is enough to promote good health and reduce the chance of developing diabetes mellitus type 2



Market Growth Drivers

The launch of generic versions of insulin and extensively growing demand for novel insulin in controlling blood sugar levels in type II diabetes mellitus are some of the few factors to fuel the growth in the market during the forecast period. New product launches by many key players are likely to boost the diabetes drug market growth during the forecast period. It is expected that the government support towards research & development expenditure and amendments in reimbursement policies in the healthcare is likely to drive the EU market. Further, Increasing geriatric population, adoption of a sedentary lifestyle, and uptake of unhealthy diet are some of the factors to fuel the EU Diabetes Mellitus Type-II Drugs market